Mothaffar F. Rimawi

机构：Baylor College of Medicine, Children's Cancer Center, Dan L Duncan Comprehensive Cancer Center · ORCID：0000-0002-4284-5656

发表论文 519 篇 · 总被引 10724 次 · h-index 55

代表论文

• Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer (2025 · New England Journal of Medicine · 被引 55)
• The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease (2026 · Journal of Clinical Oncology · 被引 8)
• Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results (2026 · Nature Cancer · 被引 1)
• Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA (2025 · Cell Genomics · 被引 1)
• A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026) (2026 · UNC Libraries)
• Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases (2026 · The Breast)